Literature DB >> 21029072

Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).

Y Machino1, H Ohta, E Suzuki, S Higurashi, T Tezuka, H Nagashima, J Kohroki, Y Masuho.   

Abstract

Intravenous immunoglobulin (IVIG) has been used widely to treat immune thrombocytopenic purpura (ITP), but the mechanisms of its action remain unclear. We investigated the affinity for Fcγ receptors (FcγRs) and the thrombocytopenia-ameliorating effect of S-sulfonated gammaglobulin (SGG) and S-alkylated gammaglobulin (AGG), in comparison with unmodified gammaglobulin (GG), in a mouse ITP model. Cleavage of immunoglobulin (Ig)G interchain disulfide bonds by either S-sulfonation or S-alkylation did not decrease the affinity for FcγRIIA (CD32A) and FcγRIIB (CD32B), but did decrease the affinity for FcγRIA (CD64A) and FcγRIIIA (CD16A), presumably because of changes in H-chain configuration. The interchain disulfide bond cleavage decreased the affinity much more for mouse FcγRIV than for mouse FcγRIIB. The ability of AGG to ameliorate ITP was greatly diminished, while SGG, whose disulfide bonds are reconstituted in vivo, was as effective as GG. These results suggest that the interchain disulfide bonds are important for therapeutic effect. It is also suggested that the interaction of IVIG with the inhibitory receptor FcγRIIB is insufficient for effective amelioration of ITP and that, at least in this model, direct binding of IVIG to FcγRIIIA is also required.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029072      PMCID: PMC3026545          DOI: 10.1111/j.1365-2249.2010.04255.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The structure of a human type III Fcgamma receptor in complex with Fc.

Authors:  S Radaev; S Motyka; W H Fridman; C Sautes-Fridman; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

Review 2.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

3.  Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.

Authors:  Hiroaki Nagashima; Tomoya Tezuka; Wakako Tsuchida; Hiroaki Maeda; Junya Kohroki; Yasuhiko Masuho
Journal:  Mol Immunol       Date:  2008-03-18       Impact factor: 4.407

Review 4.  The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

Authors:  Andrew R Crow; Alan H Lazarus
Journal:  Transfus Med Rev       Date:  2008-04

5.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

6.  Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells.

Authors:  Susheela Tridandapani; Kristina Siefker; Jean-Luc Teillaud; Jo Ellen Carter; Mark D Wewers; Clark L Anderson
Journal:  J Biol Chem       Date:  2001-12-07       Impact factor: 5.157

7.  IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.

Authors:  A R Crow; S Song; J W Semple; J Freedman; A H Lazarus
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

8.  Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Authors:  Robert L Shields; Jadine Lai; Rodney Keck; Lori Y O'Connell; Kyu Hong; Y Gloria Meng; Stefanie H A Weikert; Leonard G Presta
Journal:  J Biol Chem       Date:  2002-05-01       Impact factor: 5.157

9.  A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation.

Authors:  Daocheng Zhu; Christopher L Kepley; Min Zhang; Ke Zhang; Andrew Saxon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

10.  Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.

Authors:  J L Teeling; T Jansen-Hendriks; T W Kuijpers; M de Haas; J G van de Winkel; C E Hack; W K Bleeker
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

View more
  6 in total

1.  Intravenous immunoglobulin does not increase FcγRIIB expression levels on monocytes in children with immune thrombocytopenia.

Authors:  M Shimomura; S Hasegawa; Y Seki; R Fukano; N Hotta; T Ichiyama
Journal:  Clin Exp Immunol       Date:  2012-07       Impact factor: 4.330

2.  Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

Authors:  Mami Suzuki; Ayaka Yamanoi; Yusuke Machino; Michiko Ootsubo; Ken-ichi Izawa; Junya Kohroki; Yasuhiko Masuho
Journal:  J Biochem       Date:  2015-08-08       Impact factor: 3.387

3.  Polymeric human Fc-fusion proteins with modified effector functions.

Authors:  David N A Mekhaiel; Daniel M Czajkowsky; Jan Terje Andersen; Jianguo Shi; Marwa El-Faham; Michael Doenhoff; Richard S McIntosh; Inger Sandlie; Jianfeng He; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  Sci Rep       Date:  2011-10-19       Impact factor: 4.379

4.  A detergent-based procedure for the preparation of IgG-like bispecific antibodies in high yield.

Authors:  Jyoti Gupta; Mehboob Hoque; Masihuz Zaman; Rizwan Hasan Khan; M Saleemuddin
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

5.  Direct mass spectrometric characterization of disulfide linkages.

Authors:  Xiaoyan Guan; Le Zhang; Jette Wypych
Journal:  MAbs       Date:  2018-03-14       Impact factor: 5.857

6.  Antibody blocks acquisition of bacterial colonization through agglutination.

Authors:  A M Roche; A L Richard; J T Rahkola; E N Janoff; J N Weiser
Journal:  Mucosal Immunol       Date:  2014-06-25       Impact factor: 7.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.